Glycylcycline
Glycylcyclines represent a new group of antibiotics, that is derived from the tetracycline antibiotic minocycline. The main agent is tigecycline. Tigecycline is a broad-spectrum ATB (effective against Gram-negative, Gram-positive and anaerobic microbes, but not effective against pseudomonas and proteus). Tigecycline is a chemically 9-t-butylglycylamido derivative of minocycline.
Indications[edit | edit source]
They are indicated for complicated skin and soft tissue infections as well as intra-abdominal infections.
Mechanism[edit | edit source]
Their mechanism of action is: inhibition of proteosynthesis, (blocking protein translation in bacteria by binding to the 30S ribosomal subunit, blocking the entry of aminoacyl-tRNA molecules into the A site of the ribosome).
Antimicrobial spectrum[edit | edit source]
It is a broad-spectrum antibiotic, that acts on many clinically important bacteria. Both gram-positive, gram-negative, anaerobic and atypical, including some multidrug-resistant- penicillin resistant Streptococcus pneumoniae, Klebsiella pneumoniae and Escherichia coli, Staphylococcus aureus. Of gram - negative bacteria it shows lower susceptibility with Pseudomonas aeruginosa, Proteus mirabilis, Burkholderia cepacia and Stenotrophomonas malthophilia.
The side effects[edit | edit source]
The side effects are:
Links[edit | edit source]
Related articles[edit | edit source]
- Antibiotic for the treatment of staphylococcal infection
- Tetracycline antibiotics
- Antibiotic resistance
References[edit | edit source]
- VOJTOVÁ, Vladimíra. Glycylcykliny - Nová skupina antibiotik. Klin Farmakol Farm [online]. -2008, roč. 3, vol. 22, s. 113–115, available on <http://www.solen.cz/pdfs/far/2008/03/06.pdf>. ISSN 1803-5353.
